Table 1

Patient characteristics

Pretreatment characteristic (N = 237)Number (%), median (range)
Males 144 (61) 
Age ≥65 years 51 (21) 
Age (years) 59 (32-84) 
Rai stage III-IV 96 (40) 
ALC (K/μL) 75 (1-425) 
ALC ≥75 K/μL 119 (50) 
Hb (g/dL) 12 (6.9-16.5) 
PLT (K/μL) 142 (12-398) 
B2M ≥4 mg/L (n = 231) 95 (41) 
B2M (mg/L) 3.6 (1.3-14.1) 
Unmutated IGHV gene (n = 208) 126 (61) 
CD38 ≥30% (n = 225) 97 (43) 
CD38 (%) 16 (0.1-99.9) 
ZAP70 IHC positive (n= 214) 138 (64) 
FISH (n = 222)  
 del(13q) 73 (33) 
 negative 47 (21) 
 +12 39 (18) 
 del(11q) 47 (21) 
 del(17p) 16 (7) 
Pretreatment characteristic (N = 237)Number (%), median (range)
Males 144 (61) 
Age ≥65 years 51 (21) 
Age (years) 59 (32-84) 
Rai stage III-IV 96 (40) 
ALC (K/μL) 75 (1-425) 
ALC ≥75 K/μL 119 (50) 
Hb (g/dL) 12 (6.9-16.5) 
PLT (K/μL) 142 (12-398) 
B2M ≥4 mg/L (n = 231) 95 (41) 
B2M (mg/L) 3.6 (1.3-14.1) 
Unmutated IGHV gene (n = 208) 126 (61) 
CD38 ≥30% (n = 225) 97 (43) 
CD38 (%) 16 (0.1-99.9) 
ZAP70 IHC positive (n= 214) 138 (64) 
FISH (n = 222)  
 del(13q) 73 (33) 
 negative 47 (21) 
 +12 39 (18) 
 del(11q) 47 (21) 
 del(17p) 16 (7) 

ALC, absolute lymphocyte count; Hb, hemoglobin; IHC, immunohistochemistry; PLT, platelet.

or Create an Account

Close Modal
Close Modal